New Product Development Facility
RDT Pacific are engaged as Project Managers for the development of a purpose-built new product development pilot facility, designed by Ashton Mitchell Architects. The new facility is a critical component in the development and future expansion of Douglas Pharmaceuticals.
The project will take 20-months to complete and result in the country’s leading pharmaceutical research and development facility.
Apart from an increase in truck traffic in and out of the driveway, minimal disruption to Douglas staff is anticipated.
Founded in 1967 by Sir Graeme Douglas, Douglas Pharmaceuticals is one of the fastest growing pharmaceutical development and manufacturing companies in Oceania.
Douglas Pharmaceuticals was initially a marketer and distributor of ethical and over-the-counter medicines in New Zealand. In the 1980s the company began manufacturing generic pharmaceuticals for the local market. In the 1990s, as a consequence of New Zealand health sector reforms, Douglas increased its focus on export activities.
Douglas Pharmaceuticals’ domestic operation has grown to more than $57 million annually and today employs one of the largest field sales teams in New Zealand. The sales team services retail pharmacy, health stores, hospitals, doctors and specialists.
Currently, Douglas Pharmaceuticals is supplying close to 30 generic products to more than 60 customers in 35 countries around the world.
This considerable investment shows the level to which Douglas is committed to NPD. The new building will be three stories high and a sky bridge will link it an existing facility.
RDT Pacific is extremely proud to be contributing to this project, we look forward to delivering a successful outcome for Douglas Pharmaceuticals.